KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Construction in Progress: 2023-2024

Historic Construction in Progress for AbCellera Biologics (ABCL) over the last 2 years, with Dec 2024 value amounting to $103.2 million.

  • AbCellera Biologics' Construction in Progress rose 27.63% to $118.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.7 million, marking a year-over-year increase of 27.63%. This contributed to the annual value of $103.2 million for FY2024, which is 13.41% up from last year.
  • AbCellera Biologics' Construction in Progress amounted to $103.2 million in FY2024, which was up 13.41% from $91.0 million recorded in FY2023.
  • AbCellera Biologics' 5-year Construction in Progress high stood at $103.2 million for FY2024, and its period low was $91.0 million during FY2023.
  • Its 2-year average for Construction in Progress is $97.1 million, with a median of $97.1 million in 2023.
  • Data for AbCellera Biologics' Construction in Progress shows a peak YoY rose of 13.41% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows AbCellera Biologics' Construction in Progress stood at $91.0 million in 2023, then increased by 13.41% to $103.2 million in 2024.